BNP PARIBAS FINANCIAL MARKETS - ONCOCYTE CORP ownership

ONCOCYTE CORP's ticker is OCX and the CUSIP is 68235C107. A total of 64 filers reported holding ONCOCYTE CORP in Q4 2020. The put-call ratio across all filers is 0.32 and the average weighting 0.1%.

Quarter-by-quarter ownership
BNP PARIBAS FINANCIAL MARKETS ownership history of ONCOCYTE CORP
ValueSharesWeighting
Q2 2023$958
-35.1%
4,1640.0%0.00%
Q1 2023$1,476
-7.5%
4,164
-16.2%
0.00%
Q4 2022$1,595
-100.0%
4,969
-20.7%
0.00%
Q3 2022$4,576,000
-61.6%
6,269
-52.7%
0.00%
Q2 2022$11,927,000
-78.8%
13,257
-64.9%
0.00%
Q1 2022$56,295,000
-39.0%
37,782
-11.2%
0.00%
Q4 2021$92,312,000
+129.9%
42,540
+277.2%
0.00%
Q3 2021$40,150,000
+184.4%
11,278
+358.6%
0.00%
Q2 2021$14,115,000
-70.0%
2,459
-72.9%
0.00%
Q1 2021$47,016,000
+22.7%
9,059
-43.5%
0.00%
Q4 2020$38,312,000
+78.1%
16,030
+3.6%
0.00%
Q3 2020$21,512,000
+323.2%
15,476
+481.6%
0.00%
Q2 2020$5,083,000
-69.1%
2,661
-60.4%
0.00%
Q1 2020$16,457,000
+146.8%
6,717
+126.7%
0.00%
Q4 2019$6,667,000
+200.3%
2,963
+180.3%
0.00%
Q3 2019$2,220,000
+1119.8%
1,057
+1347.9%
0.00%
Q2 2019$182,000
-70.6%
73
-53.5%
0.00%
Q1 2019$620,000
+185.7%
1570.0%0.00%
Q4 2018$217,000
-44.6%
1570.0%0.00%
Q3 2018$392,000
-2.0%
1570.0%0.00%
Q2 2018$400,000
-77.1%
157
-81.2%
0.00%
Q1 2018$1,749,000
-49.6%
833
+11.7%
0.00%
Q4 2017$3,469,000
+30.9%
746
+112.5%
0.00%
Q3 2017$2,650,000
+35.2%
351
-6.9%
0.00%
Q2 2017$1,960,000
+260.3%
377
+219.5%
0.00%
Q1 2016$544,0001180.00%
Other shareholders
ONCOCYTE CORP shareholders Q4 2020
NameSharesValueWeighting ↓
BROADWOOD CAPITAL INC 14,716,204$20,456,0001.61%
PURA VIDA INVESTMENTS, LLC 6,022,534$8,371,0000.43%
P.A.W. CAPITAL CORP 199,700$278,0000.30%
Penbrook Management LLC 229,425$319,0000.28%
PERKINS CAPITAL MANAGEMENT INC 39,725$55,0000.05%
GSA CAPITAL PARTNERS LLP 201,047$279,0000.05%
Private Wealth Partners, LLC 150,000$209,0000.02%
Phoenix Holdings Ltd. 317,138$426,0000.02%
BRIDGEWAY CAPITAL MANAGEMENT, LLC 255,300$355,0000.01%
ETF MANAGERS GROUP, LLC 157,933$226,0000.01%
View complete list of ONCOCYTE CORP shareholders